Clarke A M, Zemcov S J, Hubinette M M
Division of Medical Microbiology, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Diagn Microbiol Infect Dis. 1994 Sep;20(1):27-32. doi: 10.1016/0732-8893(94)90015-9.
The in vitro activity of FK-037, a novel parenteral oxime-type cephalosporin, was compared with that of cefepime, cefpirome, ceftazidime, imipenem, and gentamicin against a total of 668 recent clinical isolates. Minimum inhibitory concentrations were determined by a standard agar dilution procedure, and all isolates were tested at two inocula (10(4) and 10(6) colony forming units). FK-037 inhibited 90% of isolates of Escherichia coli, Klebsiella species, Proteus mirabilis, P. vulgaris, Morganella morganii, Serratia marcescens, Providencia stuartii, Citrobacter freundii, Salmonella typhi, Shigella sonnei, Yersinia enterocolitica, Aeromonas species, and Haemophilus influenzae at < or = 1 microgram/ml. FK-037 was less active against Enterobacter species, Acinetobacter species, and Pseudomonas species, requiring 16 micrograms/ml to inhibit 90% of isolates, and was inactive against Xanthomonas maltophilia. FK-037 inhibited 90% of methicillin-susceptible Staphylococcus aureus at < or = 1 microgram/ml and 90% of methicillin-resistant S. aureus at < or = 8 micrograms/ml.
将新型肠外肟型头孢菌素FK-037的体外活性与头孢吡肟、头孢匹罗、头孢他啶、亚胺培南和庆大霉素针对总共668株近期临床分离株的活性进行了比较。通过标准琼脂稀释法测定最低抑菌浓度,所有分离株均在两种接种量(10⁴和10⁶菌落形成单位)下进行测试。FK-037在≤1微克/毫升时可抑制90%的大肠杆菌、克雷伯菌属、奇异变形杆菌、普通变形杆菌、摩根摩根菌、粘质沙雷菌、斯氏普罗威登斯菌、弗氏柠檬酸杆菌、伤寒沙门菌、宋内志贺菌、小肠结肠炎耶尔森菌、气单胞菌属和流感嗜血杆菌分离株。FK-037对肠杆菌属、不动杆菌属和假单胞菌属的活性较低,抑制90%的分离株需要16微克/毫升,对嗜麦芽窄食单胞菌无活性。FK-037在≤1微克/毫升时可抑制90%的甲氧西林敏感金黄色葡萄球菌,在≤8微克/毫升时可抑制90%的甲氧西林耐药金黄色葡萄球菌。